Literature DB >> 8953101

In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.

C E Nord1.   

Abstract

The in vitro activities of ciprofloxacin, ofloxacin, sparfloxacin, and DU-6859a against peptostreptococci, Clostridium perfringens, Clostridium difficile, Bacteroides fragilis, Porphyromonas, Prevotella, and Fusobacterium were determined by an agar dilution method. These activities were compared with those of piperacillin/tazobactam, cefoxitin, imipenem, clindamycin, and metronidazole. Imipenem, metronidazole, and DU-6859a were the most active antimicrobial agents that were tested. The in vitro activity of DU-6859a was superior to those of ciprofloxacin, lomefloxacin, ofloxacin, and sparfloxacin.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8953101     DOI： 10.1093/clinids/23.supplement_1.s15

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  11 in total

Review 1.  Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.

Authors:  C E Nord
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

2.  Genetic determinant of intrinsic quinolone resistance in Fusobacterium canifelinum.

Authors:  Georg Conrads; Diane M Citron; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.

Authors:  F Barbut; D Decré; B Burghoffer; D Lesage; F Delisle; V Lalande; M Delmée; V Avesani; N Sano; C Coudert; J C Petit
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

4.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

5.  Variation in Risk of Hospital-Onset Clostridium difficile Infection Across β-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia.

Authors:  Brian T Fisher; Julia Shaklee Sammons; Yimei Li; Peter de Blank; Alix E Seif; Yuan-Shung Huang; Marko Kavcic; Sarah Klieger; Tracey Harris; Kari Torp; Douglas Rheam; Ami Shah; Richard Aplenc
Journal:  J Pediatric Infect Dis Soc       Date:  2014-02-16       Impact factor: 3.164

6.  Accumulation of norfloxacin by Bacteroides fragilis.

Authors:  V Ricci; L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

7.  In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates.

Authors:  D Milatovic; F J Schmitz; S Brisse; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

8.  Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.

Authors:  Cédric Charrier; Anne-Marie Salisbury; Victoria J Savage; Thomas Duffy; Emmanuel Moyo; Nathan Chaffer-Malam; Nicola Ooi; Rebecca Newman; Jonathan Cheung; Richard Metzger; David McGarry; Mark Pichowicz; Ralph Sigerson; Ian R Cooper; Gary Nelson; Hayley S Butler; Mark Craighead; Andrew J Ratcliffe; Stuart A Best; Neil R Stokes
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

9.  Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.

Authors:  C Edlund; S Sabouri; C E Nord
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-03       Impact factor: 3.267

10.  Antimicrobial Susceptibility of Enteric Gram Negative Facultative Anaerobe Bacilli in Aerobic versus Anaerobic Conditions.

Authors:  Zachary DeMars; Silpak Biswas; Raghavendra G Amachawadi; David G Renter; Victoriya V Volkova
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.